Vivos Therapeutics’ Flagship CARE Oral Medical Devices Receive Full Approval for Medicare Reimbursement
April 09, 2024 07:30 ET
|
Vivos Therapeutics, Inc
LITTLETON, Colo., April 09, 2024 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company”) (NASDAQ: VVOS), a leading medical device and technology company specializing in the...
Vivos Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Operational Update
March 28, 2024 16:05 ET
|
Vivos Therapeutics, Inc
Positive Business Momentum and Sales Pipeline Growth Following FDA 510(k) Clearance of Vivos’ Proprietary Oral Medical Devices to Treat Severe Obstructive Sleep Apnea Annual Operating Expenses...
Vivos Therapeutics Schedules Release of Fourth Quarter and Full Year 2023 Financial Results and Conference Call
March 28, 2024 07:30 ET
|
Vivos Therapeutics, Inc
LITTLETON, Colo., March 28, 2024 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company”) (NASDAQ: VVOS), a leading medical device and technology company specializing in the...
Vivos Therapeutics Announces Exercise of Warrants for Approximately $4.0 Million Aggregate Gross Proceeds
February 15, 2024 08:00 ET
|
Vivos Therapeutics, Inc
LITTLETON, Colo., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company”) (NASDAQ: VVOS), a leading medical device and technology company specializing in the...
Vivos Therapeutics Highlights Significant Favorable Market Developments Creating Exciting New Growth Opportunities
February 06, 2024 07:30 ET
|
Vivos Therapeutics, Inc
LITTLETON, Colo., Feb. 06, 2024 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (the “Company” or “Vivos”) (NASDAQ:VVOS), a leading medical device and technology company specializing in the development...
Vivos Therapeutics Sees Positive Preliminary Metrics Following Unprecedented FDA 510(k) Clearance of the Company’s Proprietary Oral Medical Devices to Treat Severe OSA
January 08, 2024 07:30 ET
|
Vivos Therapeutics, Inc
Vivos Therapeutics is seeing positive preliminary metrics regarding FDA 510(k) clearance of its CARE oral medical devices to treat severe OSA.
Vivos Therapeutics Presents Groundbreaking Event: “Empowering Women to Champion Airway”
December 11, 2023 07:30 ET
|
Vivos Therapeutics, Inc
LITTLETON, Colo., Dec. 11, 2023 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (the “Company” or “Vivos”) (NASDAQ:VVOS), a leading medical device and technology company specializing in the development...
Vivos Therapeutics Receives First Ever FDA 510(k) Clearance for Oral Device Treatment of Severe Obstructive Sleep Apnea
November 29, 2023 07:30 ET
|
Vivos Therapeutics, Inc
LITTLETON, Colo., Nov. 29, 2023 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (the “Company” or “Vivos”) (NASDAQ:VVOS), a leading medical device and technology company specializing in the development...
Vivos Therapeutics Reports Third Quarter 2023 Financial Results and Provides Operational Update
November 14, 2023 16:05 ET
|
Vivos Therapeutics, Inc
Operating Expenses Decreased 32% Year Over Year and 19% Sequentially as Cost Cutting Measures Take Hold New Strategic Relationships, Including U.S. Nationwide Distribution Agreement with Lincare,...
Vivos Therapeutics Schedules Release of Third Quarter 2023 Financial Results and Conference Call
November 09, 2023 16:30 ET
|
Vivos Therapeutics, Inc
LITTLETON, Colo., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company”) (NASDAQ: VVOS), a medical technology company focused on developing innovative treatments for...